- Home
- SYNX vs APRE Comparison
SYNX vs APRE Comparison
Compare SYNX & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYNX | APRE |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.3M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SYNX | APRE |
|---|---|---|
| Price | $1.06 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 97.8K | 78.7K |
| Earning Date | 02-23-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,003,000.00 | $488,239.00 |
| Revenue This Year | $32.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $0.81 |
| 52 Week High | $4.55 | $4.65 |
Technical Indicators
Market Signals| Indicator | SYNX | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 32.10 |
| Support Level | $1.06 | $0.89 |
| Resistance Level | $1.27 | $0.88 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 23.08 | 10.05 |
Price Performance
Historical ComparisonAbout SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.